On May 8, 2026, the clinical trial titled "Screening and Stimulation Testing for Residual Secretion of Adrenal Steroid Hormones in Autoimmune Addison's Disease" was updated with a status change. The trial, registered as NCT03793114, involves cosyntropin, an approved compound. According to the registry entry, the study phase is listed as not applicable. The current status is active, not recruiting, meaning the trial is ongoing but is no longer enrolling new participants. No results have been posted as part of this update. The trial focuses on stimulation testing related to residual adrenal steroid hormone secretion in individuals with autoimmune Addison's disease. This update reflects only a change in recruitment status and does not include outcome data or findings. Readers seeking more detail on the trial's design, objectives, or eligibility criteria can consult the official registry listing. For general background on cosyntropin, including its approved uses and regulatory status, see the compound overview.
Cosyntropin Trial Update: NCT03793114 Now Active, Not Recruiting
See the full cosyntropin overview
Source: https://clinicaltrials.gov/study/NCT03793114